---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-303796"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2022-12-13T23:59:59+00:00"
generated_at: "2026-06-21T05:39:38.724104+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biomea Fusion presents preclinical data for BMF-500 at ASH; IND on track for H1 2023

## Summary
- BMF-500 demonstrated picomolar affinity to FLT3 mutations, including ITD and TKD.
- Complete tumor regression in FLT3-ITD xenograft models; effect maintained without continuous exposure.
- Three-hour pulse of BMF-500 outperformed continuous gilteritinib exposure in cell killing.
- IND submission for BMF-500 planned for first half of 2023.
- BMF-500 showed high selectivity with minimal off-target cytotoxicity across 20 cancer cell lines.

## SEC filing metadata
- accession: 0001193125-22-303796
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2022-12-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000119312522303796/0001193125-22-303796-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000119312522303796/d424536d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-303796
- JSON: https://secwatch.observer/filing/0001193125-22-303796.json
- Plain text: https://secwatch.observer/filing/0001193125-22-303796.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.